PropThink: Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues

[ACN Newswire] – By Jake KingEsbriet (perfenidone) sales in Europe have begun to pick up according to InterMune’s (NASDAQ:ITMN) third quarter results , driven largely (91%) by sales in Germany where the drug received government … more

View todays social media effects on ITMN

View the latest stocks trending across Twitter. Click to view dashboard